Meet the Consumer-Directed HMO

It took a while for a managed care company to combine a consumer-directed plan with a traditional HMO. Health Net of California, taking advantage of the strengths of California’s managed care market, is launching a hybrid product called OptimizerHMO that “provides tools to help [members] make better health care decisions and incentives for demonstrating healthy behaviors,” says Stephen Lynch, president of Health Net.

The hybrid includes a health reimbursement account (HRA) that employees can use to cover out-of-pocket medical expenses using a special debit card. Under the plan, employers deposit $500, $750, or $1,000 into the HRA earmarked for each participating employee. Employees can track their HRA balances and out-of-pocket expenses online. Sound familiar?

In addition, the product rewards healthy behavior by depositing $100 into a member’s HRA if he completes a health risk questionnaire. Filling out the questionnaire provides access to information about health improvement and health topics of interest to the member. Another $100 is deposited if the member contacts a health coach within six months of a hospitalization.

Other tools include a treatment cost estimator, a medical group and hospital quality comparison report, and an encyclopedia of health information. At enrollment, members must choose a primary care physician to serve as a gatekeeper, as with a traditional HMO.

The product was rolled out in June and is open to employers with 51 or more employees. Health Net says the hybrid plan is priced at about 18 percent to 20 percent lower than the its traditional HMO products.


Customer Analytics & Engagement in Health Insurance Chicago December 4–5, 2014
Pharmaceutical and Biotech Clinical Quality Assurance Conference Alexandria, VA December 4–5, 2014
6th Semi-Annual Diagnostic Coverage and Reimbursement Conference Boston December 4–5, 2014
9th Semi-Annual Medical Device Coverage and Reimbursement Conference San Diego December 5, 2014
8th Annual Medical Device Clinical Trials Conference Chicago December 8–9, 2014
HealthIMPACT Southeast Tampa, FL January 23, 2015

Our other journal

P&T Journal for November 2014



Medications for Parkinson’s Disease


The Changing Roles of P&T Committees

Epilepsy Management: Newer Agents, Unmet Needs, and Future Treatment Strategies


Modest Growth Seen in Epilepsy Market


European Society of Cardiology and Transcatheter Cardiovascular Therapeutics


“Generic: The Unbranding of Modern Medicine,” by Jeremy A. Greene, MD, PhD


Misadministration of IV Insulin Associated With Dose Measurement And Hyperkalemia Treatment


FDA’s Proposed 503B Draft Compounding Guidance Raises Concerns of All Kinds

New Drugs/Drug News

Pharmaceutical Approval Update


Riociguat (Adempas): a Novel Agent For the Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension